Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday newspaper round-up: Cadbury, RBS/Lloyds, Vodafone

Mon, 09th Nov 2009 06:18

Kraft, the American food company, is poised to initiate a hostile takeover bid for Cadbury today at or slightly above the offer it made in September, which valued the British confectioner at £10.2bn, according to a person familiar with the deal.Last night Kraft was finalising plans to go directly to shareholders of Cadbury before the UK Takeover Panel's "put up or shut up" deadline expires at 5pm, the Times reports.Three of the City's leading stockbrokers have written to Lord Myners, the City Minister, accusing Royal Bank of Scotland and Lloyds Banking Group of "corporate bullying" by forcing companies that owe money to the banks to use their investment banking services.In an unprecedented act of solidarity, three of the Square Mile's fiercest rivals ? Tim Linacre, chief executive of Panmure Gordon; Oliver Hemsley, chief executive of Numis; and Alex Snow, chairman of Evolution ? allege that when a company holds a rights issue to reorganise its debt, the banks will continue to lend to it only if it uses their brokerage and capital markets units for the deal, the Times reports.Insurance giant Axa Group is readying a €2bn (£1.8bn) rights issue that could be launched as early as Monday. France's biggest insurer is plotting the capital-raising to fund potential acquisitions in a sector that has been ravaged by the financial crisis. Bankers at BNP Paribas and HSBC have been appointed to work on the capital-raising, the Telegraph reports.Meanwhile, Axa Asia Pacific, the Australian-listed asset manager, has rejected an A$11bn (US$10.2bn) takeover bid from Australia's AMP, saying on Monday the cash and shares proposal undervalued its business. The offer is one of the largest in the global financial services industry since the onset of the financial crisis, excluding transactions involving government bail-outs, and is also among the biggest in Asia this year, the FT reports.Vittorio Colao, Vodafone's chief executive, is preparing a fresh round of cost cutting as he tries to offset falling revenue at the mobile phone operator. Vodafone's shares have underperformed the FTSE 100 by 16 per cent this year, partly because of concern at how the UK company's underlying revenue at most of its core European businesses is falling, the FT reports.Gordon Brown, the British prime minister, rapidly backpedalled from his proposal for a financial transactions tax on Sunday after a chorus of criticism of his plan set out in a speech on Saturday to a meeting of global finance ministers. The US led a backlash against the "Tobin tax" on financial transactions after Mr Brown took a Group of 20 finance ministers' meeting by surprise with his proposal at the gathering in St Andrews, Scotland, the FT says.Britain's employers plan to continue shedding jobs during the final three months of 2009, confirming the widely held view that unemployment will continue to rise for the foreseeable future even if the UK economy comes out of recession. The outlook for UK employment prospects is now deteriorating more slowly than at any time since recession took hold in the middle of 2008, but it is still deteriorating, according to KPMG's quarterly labour market outlook, which it publishes with the Chartered Institute of Personnel and Development (CIPD), the Independent reports.Wal-Mart has sold Asda for £6.9bn to a Leeds-based investment vehicle called Corinth Services Limited for only £200m more than it paid for the UK supermarket chain in 1999. In the previously undisclosed group restructuring that took place in August, the world's largest retailer let its subsidiary Wal-Mart Stores (UK) sell 3.1bn ordinary shares in Asda in return for a £5.7bn cash payment from Corinth, a fellow Wal-Mart group company, and £1.24bn in shares, the Telegraph reports.Radioactive waste from a new generation of British nuclear power stations will be buried deep underground in a storage facility that could cost up to £18bn to build, under plans to be announced by the Government today, the Times reports.Long-dated oil prices have risen to within a whisker of $100 a barrel, in a sign that investors are expecting high prices to return after the recession. The furthest forward oil contract traded on exchanges - the December 2017 futures - rose last week to $99.97 a barrel for the Brent benchmark and to $99.43 for the West Texas Intermediate, the highest since last October. The prices have risen by 10 % in the past month, the FT reports.
More News
27 Jul 2018 13:14

Friday broker round-up

(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.

Read more
26 Jul 2018 12:54

Evgen Pharma Expects Final Results From Clinical Trials At End Of Year

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it expects to receive the final read-out from two clinical trials by the end of 2018.The drug development company said at its annual

Read more
25 Jul 2018 14:48

Evgen concludes patient recruitment in STEM breast cancer trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.

Read more
25 Jul 2018 13:57

Wednesday broker round-up

(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.

Read more
25 Jul 2018 13:31

Evgen Pharma Metastatic Breast Cancer Trial Ends Patient Recruitment

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it has concluded its patient recruitment for its STEM Phase IIa trial of SFX-01 in metastatic breast cancer.Following the favourable

Read more
19 Jul 2018 16:21

UK Shareholder Meetings Calendar - Next 7 Days

Friday 20 JulyHomeserveKCOM GroupMonday 23 JulyEthernity Energy 24

Read more
13 Jun 2018 10:46

Evgen Pharma Annual Loss Narrows As It Continues Phase II Trials

LONDON (Alliance News) - Clinical drug development company Evgen Pharma PLC said Wednesday its annual loss narrowed in line with expectations.Evgen, which focuses on cancer and neurological

Read more
11 Jun 2018 11:33

Evgen STEM Interim Trial Result Show "Signs Of Anti-Tumour Activity"

LONDON (Alliance News) - Evgen Pharma PLC said Monday its STEM trial showed "early signs of anti-tumour activity" in breast cancer patients.STEM is the company's study of in a

Read more
2 May 2018 11:15

Evgen Pharma Gets European Patent For Sulforaphane Stablising Method

LONDON (Alliance News) - Drug development company Evgen Pharma said Wednesday that it has secured a European patent recognising its intellectual property for a method of stabilising sulforaphane,

Read more
20 Mar 2018 13:56

Evgen Pharma Begins Research Partnership With Imperial College London

LONDON (Alliance News) - Drug development company Evgen Pharma PLC has started a new research collaboration with Imperial College London focusing on SFX-01, the company's

Read more
13 Feb 2017 08:21

Evgen Pharma signs service agreement with drug development corsortium

(ShareCast News) - AIM-listed Evgen Pharma has signed a services agreement with a consortium of Cheshire-based drug developments firms for its sulforaphane product. APT Trans, the consortium of drug developers based in the Biohub at Alderley Park, which comprises of Aptus Clinical, Apconix and Seda

Read more
17 Jan 2017 12:35

Richard Moulson to join Evgen Pharma as CFO

(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday. The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 Febru

Read more
11 Jan 2017 09:23

Evgen Pharma receives go ahead for haemorrhage drug trial

(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial

Read more
11 Jan 2017 09:17

Evgen Pharma Gets Positive Review For SFX-01 Phase II Study

Read more
17 Aug 2016 10:49

Evgen Pharma receives approval for breast cancer study

(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the UK's regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer. The AIM-traded firm said patient recruitment w

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.